FreeTheAI

Coya Therapeutics Prioritizes ALS Trial and Delays Dementia Study to 2027

MixedMedium impact
COYA$4.48 −6.96%

Coya Therapeutics, Inc. (COYA) plans to launch an open-label extension for its Phase 2/3 ALSTARS trial testing COYA 302 in amyotrophic lateral sclerosis (ALS), expected to begin in November 2026. As part of a strategy to focus resources on its primary ALS program, the company is delaying the start of its Phase 2 trial in frontotemporal dementia (FTD) until 2027.

Narrowing its operational scope allows Coya Therapeutics, Inc. (COYA) to direct capital and clinical resources toward its lead asset while extending patient treatment and data collection in ALS. However, pushing back the FTD study delays the timeline for broadening its drug pipeline into additional neurodegenerative conditions.

Looking ahead, management kept its financial timeline intact, anticipating that existing cash reserves will support operations into the second half of 2027. Market participants will watch for the start of the extension study in late 2026 alongside ongoing progress in the ALSTARS trial.

Key points

  • Coya Therapeutics, Inc. (COYA) plans to start an open-label extension for its Phase 2/3 ALS trial in November 2026.
  • The company is prioritizing development resources on its lead ALS program.
  • The start of the Phase 2 frontotemporal dementia trial is pushed back to 2027.
  • Cash runway guidance remains unchanged into the second half of 2027.

Written by our AI from expert market sources across the web. It can contain mistakes: check the facts before acting on them. Write-ups powered by the free AI API at FreeTheAI.org

How we writeDisclaimer

Questions and answers

What is Coya Therapeutics updating regarding its ALS trial?

Coya Therapeutics plans to start an open-label extension of its Phase 2/3 ALSTARS trial testing COYA 302 in ALS in November 2026.

Why is Coya Therapeutics delaying its dementia trial?

The company is prioritizing its lead ALS program, shifting the planned start of its Phase 2 frontotemporal dementia trial to 2027.

How long is Coya Therapeutics cash runway?

Coya Therapeutics expects its current cash runway to fund operations into the second half of 2027.